Grifols (Grifols) FCF Margin %

: 0.00% (As of Sep. 2023)

View and export this data going back to 2011. Start your Free Trial

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Grifols's Free Cash Flow for the three months ended in Sep. 2023 was $0 Mil. Grifols's Revenue for the three months ended in Sep. 2023 was $1,705 Mil. Therefore, Grifols's FCF Margin % for the quarter that ended in Sep. 2023 was 0.00%.

As of today, Grifols's current FCF Yield % is -2.23%.

The historical rank and industry rank for Grifols's FCF Margin % or its related term are showing as below:

GRFS' s FCF Margin % Range Over the Past 10 Years
Min: -6.37 Med: 6.07 Max: 20.62
Current: -1.75

During the past 13 years, the highest FCF Margin % of Grifols was 20.62%. The lowest was -6.37%. And the median was 6.07%.

GRFS's FCF Margin % is ranked worse than
53.13% of 1024 companies
in the Drug Manufacturers industry
Industry Median: -0.68 vs GRFS: -1.75

Grifols FCF Margin % Historical Data

The historical data trend for Grifols's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grifols Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

3.07

14.00

5.71

-6.37

-1.32

Grifols Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23
FCF Margin %																-	-	-	-	-

Competitive Comparison

For the Drug Manufacturers - General subindustry, Grifols's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Grifols FCF Margin % Distribution

For the Drug Manufacturers industry and Healthcare sector, Grifols's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Grifols's FCF Margin % falls into.

Grifols FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Grifols's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-95.024	/	7188.634
	=	-1.32 %

Grifols's FCF Margin for the quarter that ended in Sep. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2023 )	/	Revenue (Q: Sep. 2023 )
	=	0	/	1704.89
	=	0.00 %

Grifols FCF Margin % Related Terms

Thank you for viewing the detailed overview of Grifols's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Grifols (Grifols) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grifols SA (NAS:GRFS) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

GIKLY:USA GIFOF:USA GIFLF:USA GRFP:Mexico GRFe:UK GRFPe:UK 0RDV:UK 0RDU:UK GRF.P:Spain GRF:Spain G0F0:Germany G0F:Germany G0FB:Germany OZTA:Germany OZTA:Germany G0FB:Germany

Address

Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174

Website

https://www.grifols.com

As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and the firm's biopharma business contributed 83% of sales in 2022. Grifols also has smaller segments including diagnostics and biosupplies. Diagnostics is roughly 10% of revenue following the Biotest acquisition.